Scientific deep-dive

Semaglutide Week by Week: When the Weight Actually Comes Off

The starting dose is not a treatment dose. In STEP 4, participants spent 16 weeks stepping up to full strength, and weight came off fastest during that run-in. What three STEP trials and an extension recorded at each stage, and what came back after stopping.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·6 citations

If you are three weeks in and the scale has barely moved, nothing has gone wrong. The starting dose of semaglutide is not a treatment dose; it exists so your gut can meet the drug slowly. In the trial designed to measure the climb, participants spent 16 weeks stepping up to the full 2.4 mg, and by week 20 they had lost about 10.6% of their body weight.[3] That run-in was the fastest stretch of the curve. Loss continued at the full dose, more slowly, and leveled off after about 14 months. Below is what three STEP trials and the STEP 1 extension recorded, stage by stage, and what happened to the people who stopped.

The first weeks are a dose ladder, not a result

Semaglutide is started low and raised in steps, and the reason is tolerance rather than caution about efficacy. Even with the slow climb, stomach side effects in STEP 4 were more common during the 20-week run-in than in the 48 weeks at full dose that followed.[3] The early weeks belong to that climb.

This matters for expectations more than anything else on this page. A reader who has been told “people lose 15% on this drug” and is standing on a scale in week 4 is comparing themselves against a 68-week endpoint while still on an introductory dose.

The number to remember. In STEP 4, everybody spent 16 weeks climbing to the full dose and 4 more weeks on it, and the average loss across those 20 weeks was about 10.6%.[3] So the ladder is not wasted time. On average it is where weight comes off fastest, and it is also where most of the stomach side effects fall.

At some sellers the ladder is a price ladder too. Vivanta Care prices compounded semaglutide by dose stage, from a starting stage up to a higher one, and shows your stage price before the health questions. Welling Health’s price sheet also follows the dose, though its site said prescribing was not yet open. Cielo, LevelUp Rx and Robinhood Telehealth charge the same at every dose, so moving up a step does not change the bill.

What 68 weeks produced

STEP 1 is the trial every later result is measured against. It enrolled 1,961 adults living with obesity and without diabetes, gave them weekly semaglutide 2.4 mg or placebo, and ran for 68 weeks. The treated group finished at −14.9% of body weight against −2.4% on placebo.[1]

The average conceals a wide spread, and the spread is the more useful fact. Just over half the treated group lost at least 15% of their body weight. On placebo, about one in twenty did.[1] Some people in that trial did far better than 14.9% and some did considerably worse, which is why this page cannot tell you what you personally will lose.

What each STEP trial measured, and what it found. Every figure is a group mean.
TrialWhat it askedDurationResult
STEP 1[1]Semaglutide 2.4 mg against placebo in obesity without diabetes68 weeks−14.9% vs −2.4%
STEP 3[2]Does the drug add anything on top of intensive behavioral therapy?68 weeks−16.0% with the drug vs −5.7% with therapy alone
STEP 4[3]After a 20-week run-in (16 weeks of climbing to full dose), what does continuing buy you?20-week run-in, then 48 weeksContinuers lost a further 7.9%; those switched to placebo regained 6.9%
STEP 1 extension[4]What happens in the year after everything stops?1 year off treatmentOf 17.3% lost, 11.6 points came back

The curve is steepest early and flattens at the end

STEP 4 gives the shape. The 20-week run-in, most of it dose escalation, produced about 10.6%. Continuing at the full dose for another 48 weeks added roughly 7.9% more.[3] That is about half a percent a week during the run-in against about a sixth of a percent a week afterward. The loss is fastest during the climb, slows through the full-dose months, and in STEP 4 leveled off between weeks 60 and 68.[3]

A plateau after a year or more on the drug is therefore the expected shape of the curve rather than a sign the drug has stopped working. That matters if a plateau has you wondering whether to stop.

If a plateau has you considering a dose change, that is a conversation with the clinician who prescribed it, not a decision to take from a chart. Our titration planner lays out the standard schedule from each drug’s own label, but what your prescriber does with “as tolerated” is theirs to judge.

The drug and the program add up

STEP 3 asked whether semaglutide and serious behavioral therapy overlap or stack. Everyone in it got the intensive program (roughly 30 visits and a restricted calorie target), and half also got the drug. The drug arm finished at 16.0%; the therapy-only arm at 5.7%.[2] The two effects added together.

That finding matters outside the clinic too. Prior-authorization criteria routinely require a documented lifestyle program alongside the prescription, and STEP 3 is the evidence that the requirement is not merely bureaucratic. If you are assembling that documentation, our guide to getting a GLP-1 covered sets out what payers ask to see.

Telehealth programs differ in how much of that support comes with the prescription. BeyondMD lists weight-loss coaching in its compounded semaglutide program alongside the provider consult, and Ivim Health sells compounded semaglutide on a 12-month program whose membership covers unlimited provider visits and health coaching. Regenics, a clinic in Tarzana, California, runs care through nurse practitioners and offers in-person visits as well as telehealth. Bliv sits at the other end, with an online intake and no phone or video visit.

What happens when it stops

This is the part of the timeline least often described to people starting out, and it changes what the whole course means.

STEP 4 ran the experiment inside the trial. After the 20-week run-in, half the participants were moved to placebo while the other half continued. The continuers lost a further 7.9%. The switchers regained 6.9%, giving back most of what the run-in had achieved while everything else about their care stayed the same.[3]

The STEP 1 extension followed 327 people for a year after treatment ended altogether. Having lost 17.3%, they regained 11.6 percentage points of it, finishing about 5.6% below where they started. Blood pressure, lipids, A1C and inflammatory markers drifted back toward baseline alongside the weight.[4]

Of the 17.3% lost in STEP 1, 11.6 percentage points came back within a year of stopping.

That result is why obesity medicine now describes these drugs as treatment for a chronic condition rather than a course with an end date. It is also the fact most worth knowing before the first injection, because it turns the question from “how much will I lose” into “what happens when I can no longer get this”. For a great many people, that is a question about cost and supply rather than biology. We keep a dated price for every seller on the price tracker. What happens to the body afterward is covered in what happens when you stop a GLP-1, and the practical side, from appetite to how fast weight returns, in stopping Ozempic or Wegovy.

What this timeline cannot tell you

  • It is a group average, not a forecast. Every figure above is a mean across hundreds or thousands of people, and individuals scattered widely around it in both directions.
  • Trial conditions are not ordinary conditions. Participants had structured support, free medication and regular contact with a study team.
  • It describes brand semaglutide at 2.4 mg. A higher 7.2 mg dose, sold as Wegovy HD, was approved in March 2026 for people who have tolerated 2.4 mg for a month and need more.[6] In its 72-week trial it reached −18.7% against −15.6% on 2.4 mg, a gap of about three points.[5] What that dose costs in side effects is in Wegovy 7.2 mg: what it costs. A compounded vial is a different product again, taken up in compounded semaglutide versus brand.
  • It is not a tirzepatide timeline. Zepbound and Mounjaro climb a different ladder and were measured in different trials, so their curve cannot be read off this one.

One thing we could not establish from the published record: how much of the early-weeks loss is attributable to the drug rather than to the dietary changes people make in the first month of any serious attempt. STEP 3 shows the two add over 68 weeks, but it does not resolve the first four.

Frequently Asked Questions

Weight comes off during the dose-escalation weeks, and on average faster than at any later stage. In STEP 4 the average loss across the 20-week run-in (16 weeks climbing to the full 2.4 mg dose, then 4 weeks on it) was about 10.6%. Loss continues at the full dose, at a slower pace.
Yes. The opening dose is an introductory one, chosen so the gut can tolerate the drug rather than to produce weight loss. Judging the medication by week four is comparing yourself against a 68-week endpoint while still on the lowest rung.
In STEP 4 the curve flattened between weeks 60 and 68. The 20-week run-in produced about 10.6% and a further 48 weeks at full dose added roughly 7.9% more, so later months contribute less than earlier ones. A plateau at that point is the expected shape rather than a failure.
Most of the weight returns. In the STEP 1 extension, 327 people who had lost 17.3% regained 11.6 percentage points within a year of stopping, ending about 5.6% below their starting weight, with blood pressure, lipids and A1C drifting back alongside.
Some people lose considerably more and some considerably less. Just over half of the treated group in STEP 1 lost at least 15%, which means almost half did not. No calculator or article can tell you which side you will fall on.

References

  1. 1.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine. 2021. PMID: 33567185.
  2. 2.Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight (STEP 3) JAMA. 2021. PMID: 33625476.
  3. 3.Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity JAMA. 2021. PMID: 33755728.
  4. 4.Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension Diabetes, Obesity and Metabolism. 2022. PMID: 35441470.
  5. 5.Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial The Lancet Diabetes & Endocrinology. 2025. PMID: 40961952.
  6. 6.Novo Nordisk FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile PR Newswire, March 19, 2026. 2026. https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-new-wegovy-hd-injection-delivering-the-highest-weight-loss-to-date-for-a-wegovy-injection-adding-to-its-already-expansive-clinical-profile-302718982.html

Constipation on a GLP-1: What the Labels Report and What Actually Helps

The Wegovy label reports constipation in 24% against 11% on placebo; the Zepbound label reports it by dose. This explains why it outlasts the nausea and where the confident advice online runs ahead of the evidence.

6 min read

GLP-1 Overdose: What Happens and What to Do

Most GLP-1 overdoses are dosing mistakes with compounded vials and cause severe nausea and vomiting that can last days. The guidance on the Ozempic, Wegovy, Mounjaro and Zepbound labels, FDA's dosing-error alert, and when to call Poison Help or 911.

10 min read

Injection Site Reactions: Where Semaglutide and Tirzepatide Really Differ

Semaglutide produced injection site reactions in 1.4% against 1% on placebo. Tirzepatide runs 6–8% against 2%. If you react on one and not the other, that is not your technique.

5 min read

Antidepressants and a GLP-1: Ozempic, Wellbutrin, Lexapro and What the Labels Say

No GLP-1 label names an antidepressant as an interaction, and people on antidepressants lost as much weight on semaglutide as everyone else. The real overlaps: stacked nausea, slowed absorption of tablets, and two bupropion rules.

11 min read

Tirzepatide Week by Week: What the SURMOUNT Trials Recorded

The dose ladder takes months, not weeks. This sets out what SURMOUNT-1, 2 and 4 recorded at each stage on Zepbound and Mounjaro, and the roughly half of the lost weight that came back when people stopped.

7 min read

GLP-1s and Hormonal Birth Control: Which Labels Carry the Warning

Three of six GLP-1 labels warn about the contraceptive pill. Mounjaro and Zepbound set a four-week window after starting and after every dose increase, and Foundayo a 30-day one; the three semaglutide labels carry no such advisory. We read all six.

9 min read

Where to get tirzepatide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.4

MyDrHank

An oral route if you will not self-inject

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

6.3

WellMedRx

Comparing compounded and brand GLP-1 plans with a published state list

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →